Pure Global AI
NCT05465434Not yet recruiting

Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.

Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy
Tanta UniversityPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Hepatitis C
Drug/Device/Intervention
Zinc Supplement
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tanta University
Timeline & enrollment
Phase
Phase 3
Start date
Aug 01, 2022
End date
Nov 30, 2023
Enrollment
50 participants
Primary outcome

Abdominal Ultrasonography,Serum fibronectin level,Serum transforming growth factor - beta 1 (TGF- β1) level,Fibrosis-4 (FIB-4) Score,AST to Platelet Ratio Index (APRI) score,Serum hyaluronic acid level

Summary

This study aims to evaluate the possible antifibrotic effect of zinc sulphate in chronic HCV
 patient receiving direct acting anti-viral therapy

ICD-10 classifications
Acute hepatitis CChronic viral hepatitis CViral hepatitisChronic viral hepatitisUnspecified viral hepatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05465434
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05465434 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Not yet recruiting. The study focuses on Hepatitis C. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.